IL161573A0 - [1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS - Google Patents

[1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS

Info

Publication number
IL161573A0
IL161573A0 IL16157302A IL16157302A IL161573A0 IL 161573 A0 IL161573 A0 IL 161573A0 IL 16157302 A IL16157302 A IL 16157302A IL 16157302 A IL16157302 A IL 16157302A IL 161573 A0 IL161573 A0 IL 161573A0
Authority
IL
Israel
Prior art keywords
adenosine
receptor antagonists
triazole
bicyclic
triazole bicyclic
Prior art date
Application number
IL16157302A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of IL161573A0 publication Critical patent/IL161573A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL16157302A 2001-11-30 2002-11-26 [1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS IL161573A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33438501P 2001-11-30 2001-11-30
PCT/US2002/037915 WO2003048163A1 (en) 2001-11-30 2002-11-26 [1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS

Publications (1)

Publication Number Publication Date
IL161573A0 true IL161573A0 (en) 2004-09-27

Family

ID=23306955

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16157302A IL161573A0 (en) 2001-11-30 2002-11-26 [1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS

Country Status (18)

Country Link
US (2) US6875772B2 (enExample)
EP (1) EP1453836B1 (enExample)
JP (2) JP4429724B2 (enExample)
KR (1) KR20050044600A (enExample)
CN (1) CN1688581A (enExample)
AR (1) AR037681A1 (enExample)
AT (1) ATE358130T1 (enExample)
AU (1) AU2002352933A1 (enExample)
CA (1) CA2468658C (enExample)
DE (1) DE60219196T2 (enExample)
ES (1) ES2283625T3 (enExample)
HU (1) HUP0402324A3 (enExample)
IL (1) IL161573A0 (enExample)
MX (1) MXPA04005158A (enExample)
PE (1) PE20030653A1 (enExample)
TW (1) TW200300689A (enExample)
WO (1) WO2003048163A1 (enExample)
ZA (1) ZA200404168B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200300686A (en) 2001-11-30 2003-06-16 Schering Corp Adenosine A2a receptor antagonists
ES2283625T3 (es) * 2001-11-30 2007-11-01 Schering Corporation Antagonistas del receptopr a2a de adenosina de (1,2,4)-triazol biciclicos.
MXPA04008730A (es) * 2002-03-12 2004-12-06 Wyeth Corp Proceso para preparacion de piperazinas quirales 1,4-disustituidas.
AU2003272886A1 (en) * 2002-09-24 2004-04-19 Kyowa Hakko Kogyo Co., Ltd. (1,2,4)-TRIAZOLO(1,5-c)PYRIMIDINE DERIVATIVE
AU2003304527B2 (en) * 2002-12-19 2010-09-09 Merck Sharp & Dohme Corp. Uses of adenosine A2a receptor antagonists
US7285550B2 (en) 2003-04-09 2007-10-23 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines and methods of making and using the same
EP1618109A2 (en) * 2003-04-09 2006-01-25 Biogen Idec MA Inc. Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists
DE602004018637D1 (de) 2003-04-09 2009-02-05 Biogen Idec Inc A2a-adenosinrezeptorantagonisten
WO2004092177A1 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
TW200507850A (en) 2003-07-25 2005-03-01 Kyowa Hakko Kogyo Kk Pharmaceutical composition
JPWO2006129626A1 (ja) * 2005-05-30 2009-01-08 協和醗酵工業株式会社 ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体の製造法
EP1902716A4 (en) * 2005-06-07 2009-05-13 Kyowa Hakko Kirin Co Ltd PROPHYLACTIC AND / OR THERAPEUTIC AGENT FOR MOTOR TROUBLESHOOTING
US20090124663A1 (en) * 2005-06-08 2009-05-14 Neurosearch A/S Novel n-phenyl-piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2007027987A2 (en) 2005-09-02 2007-03-08 Mount Cook Biosciences, Inc. Method of treating parkinson's disease with diarylmethylpiperazine compounds exhibiting delta receptor agonist activity
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
US7615556B2 (en) * 2006-01-27 2009-11-10 Bristol-Myers Squibb Company Piperazinyl derivatives as modulators of chemokine receptor activity
CN102014959B (zh) 2008-03-10 2016-01-20 康奈尔大学 血脑屏障通透性的调节
WO2010008775A1 (en) * 2008-06-23 2010-01-21 Ligand Pharmaceuticals Inc. Aminopyridopyrazinone derivatives for treating neurodegenerative diseases
GB201214106D0 (en) * 2012-08-07 2012-09-19 Univ Strathclyde Immunomodulatory compounds
EP3436013A4 (en) 2016-03-31 2019-11-13 Versi Group, LLC DELTA OPIOID AGONIST, MU OPIOID ANTAGONIST COMPOSITIONS AND METHOD FOR TREATING MORBUS PARKINSON
CN106866582A (zh) * 2017-01-10 2017-06-20 广州隽沐生物科技有限公司 一种氟班色林中间体的制备方法
CA3103068C (en) * 2018-06-26 2024-06-25 Zhejiang Vimgreen Pharmaceuticals, Ltd Triazolotriazine derivatives as a2a receptor antagonists
WO2020227156A1 (en) * 2019-05-03 2020-11-12 Nektar Therapeutics Adenosine 2 receptor antagonists
JP2023508182A (ja) * 2019-12-26 2023-03-01 チェジン ヴィムグリーン ファーマシューティカルズ リミテッド トリアゾロトリアジン誘導体の疾患治療への応用
KR102863028B1 (ko) * 2021-04-23 2025-09-22 주식회사 종근당 아데노신 A2a 수용체 길항제로서의 화합물 및 이를 포함하는 약학적 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
ATE208199T1 (de) * 1993-07-27 2001-11-15 Kyowa Hakko Kogyo Kk Arzneimittel gegen parkinsonsche krankheit
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
CA2284737C (en) * 1997-03-24 2007-03-13 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]triazolo[1,5-c]pyrimidine derivatives
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
AU2639299A (en) 1998-02-24 1999-09-15 Kyowa Hakko Kogyo Co. Ltd. Remedies/preventives for parkinson's disease
WO2000017201A1 (en) * 1998-09-22 2000-03-30 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES
US6355653B1 (en) 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
JP2002037787A (ja) * 2000-05-16 2002-02-06 Kyowa Hakko Kogyo Co Ltd ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体の製造法
SI1283839T1 (enExample) 2000-05-26 2005-08-31 Schering Corp
AR037243A1 (es) 2001-10-15 2004-11-03 Schering Corp Antagonistas del receptor de adenosina a2a,a5-amino-imidazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]pirimidina, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
ES2283625T3 (es) * 2001-11-30 2007-11-01 Schering Corporation Antagonistas del receptopr a2a de adenosina de (1,2,4)-triazol biciclicos.

Also Published As

Publication number Publication date
CA2468658C (en) 2009-04-14
JP4429724B2 (ja) 2010-03-10
US20050113380A1 (en) 2005-05-26
ZA200404168B (en) 2005-09-02
WO2003048163A1 (en) 2003-06-12
MXPA04005158A (es) 2004-08-11
CA2468658A1 (en) 2003-06-12
DE60219196T2 (de) 2008-01-03
EP1453836B1 (en) 2007-03-28
AR037681A1 (es) 2004-12-01
DE60219196D1 (de) 2007-05-10
PE20030653A1 (es) 2003-08-04
EP1453836A1 (en) 2004-09-08
JP2005511697A (ja) 2005-04-28
US20030191130A1 (en) 2003-10-09
JP2010018634A (ja) 2010-01-28
US7078408B2 (en) 2006-07-18
AU2002352933A1 (en) 2003-06-17
US6875772B2 (en) 2005-04-05
KR20050044600A (ko) 2005-05-12
HUP0402324A3 (en) 2008-09-29
CN1688581A (zh) 2005-10-26
TW200300689A (en) 2003-06-16
ATE358130T1 (de) 2007-04-15
HK1064097A1 (en) 2005-01-21
HUP0402324A2 (hu) 2005-02-28
ES2283625T3 (es) 2007-11-01

Similar Documents

Publication Publication Date Title
IL161716A0 (en) ADENOSINE A2a RECEPTOR ANTAGONISTS
IL161572A0 (en) Adenosine a2a receptor antagonists
IL152726A0 (en) Adenosine a2a receptor antagonists
HUP0401925A3 (en) A2b adenosine receptor antagonists
HUP0401437A3 (en) Adenosine a3 receptor agonists
PL353969A1 (en) Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof as adenosine receptor ligands
DE60219196D1 (de) BICYCLISCHE Ä1,2,4ö-TRIAZOL ADENOSIN A2a REZEPTOR ANTAGONISTEN
MXPA03004439A (es) Aminotiazoles y su uso como antagonistas del receptor de adenosina.
IL147195A0 (en) C-pyrazole a2a receptor agonists
AU5640199A (en) 4-quinolinemethanol derivatives as purine receptor antagonists (i)
SI1622912T1 (sl) 2-alkinil- in 2-alkenil-pirazolo-(4,3-E)-1,2,4-triazolo-(1,5-C)-pirimidin adenozinski A2a receptorski antagonisti
PL373953A1 (en) 7-amino-benzothiazole derivatives as adenosine receptor ligands
EP1086066A4 (en) MUSCARINIC RECEPTOR ANTAGONISTS
ZA200408755B (en) Condensed purine derivatives as A1 adenosine receptor antagonists.
PL353366A1 (en) Pyrazolo[4,3-d]pyrimidines
IL142045A0 (en) Naphthalenecarboxamides as tachykinin receptor antagonists
IL162444A0 (en) Triazolo-quinolin derivatives useful as adenosine receptor ligands
PL370565A1 (en) 5-methoxy-8-aryl-[1,2,4] triazolo [1,5-a] pyridine derivatives as adenosine receptor antagonists
AU4980999A (en) A3 adenosine receptor antagonists
AU2002359524A8 (en) P2x7 receptor antagonists
IL156087A0 (en) Histamine receptor antagonists
IL158063A0 (en) Crf receptor antagonists
SI1444233T1 (sl) Antagonisti adenozinskega receptorja A2B
AU2002226519A1 (en) Pyrrolo(2,3-d)pyrimidine and their use as purinergic receptor antagonists
HK1062534A (en) Imidazo (4,3-e)-1,2,4-triazolo(1,5-c) pyrimidines as adenosine a2a receptor antagonists